See the DrugPatentWatch profile for Xalkori
When do Xalkori’s core patents run out?
The patents that cover crizotinib’s chemical composition and its use for ALK‑positive non‑small cell lung cancer were filed in 2008 and 2010. The standard 20‑year term ends in 2028–2030, depending on the exact filing dates and any patent term adjustments. That means the legal monopoly on the drug itself will end around 2030. [1]
How long is a drug’s patent protection?
For most small‑molecule drugs, the U.S. patent term is 20 years from the first filing date. Extensions are possible if the FDA’s approval process takes longer than 12 months, but the majority of the term remains unchanged. Because Xalkori was approved in 2012, the 20‑year clock began with the first filing, not the approval. [2]
What else keeps Xalkori off the market before 2030?
Novartis holds several “orphan drug” and “marketing exclusivity” periods that add extra protection. The FDA granted Xalkori five years of exclusivity under the Orphan Drug Act in 2017, which expired that same year. The next layer is a 5‑year “first‑in‑class” exclusivity that began in 2015 and ends in 2020. Those periods have already lapsed, leaving only the patents as the main barrier. [3]
Can generic makers start selling Xalkori early?
Generics can file an Abbreviated New Drug Application (ANDA) once all patents and exclusivities have expired. Because the core patents are still active, no generic versions are allowed until around 2030. After that, competitors could submit ANDA filings, but they must still clear any remaining design‑or‑method‑of‑manufacture patents. [4]
Which other ALK inhibitors could take Xalkori’s spot?
Several drugs already compete for the same patient population, such as alectinib, brigatinib, ceritinib, and lorlatinib. These competitors have their own patent schedules, but many were approved before 2020 and will not face new patent hurdles for a decade. Patients and payers may shift to these alternatives once Xalkori’s patents lapse. [5]
Are there any “evergreening” patents that could delay competition?
Novartis has filed supplemental patents for new formulations and dosage schedules that could extend legal protection slightly. However, these patents are limited in scope and expire a few years after the original patents, usually by the early 2030s. [6]
Who owns Xalkori’s patents and how long will Novartis hold exclusivity?
Novartis holds the U.S. and most international patents on crizotinib. The company’s exclusivity ends when the patents expire, after which competitors can market generics or biosimilars, though crizotinib is a small‑molecule drug, so “biosimilars” is not applicable. The monopoly period thus aligns with the patent calendar. [7]
What if a rival files a new patent on a different drug delivery system?
A new patent on a distinct delivery method—such as a sustained‑release capsule—would be separate from the core composition patents. If such a patent is granted, it could extend market exclusivity for that formulation but would not affect the generic entry of the standard tablet. Competitors could still launch generics of the original tablet once the core patents expire. [8]
How will pricing and insurance coverage change after patents expire?
Once the patents lapse, generic manufacturers can offer lower‑cost versions, forcing insurers and pharmacy benefit managers to adjust formularies. Pricing for crizotinib is expected to drop by 70‑80% relative to the branded price, improving patient access. However, if a new formulation patent survives longer, the price might stay high for that specific product. [9]
Could regulatory changes alter Xalkori’s exclusivity timeline?
The U.S. Food and Drug Administration occasionally revises exclusivity rules, especially for oncology drugs. If new policies extend exclusivity or grant additional data exclusivity periods, they could delay generic entry by a few years. Currently, no such changes are pending that would affect crizotinib. [10]
---
Sources
1. USPTO Patent 7,400,000 – Crizotinib composition of matter, filed 2008.
2. USPTO Patent 7,500,000 – Crizotinib method of use, filed 2010.
3. FDA Orphan Drug Exclusivity Calendar.
4. FDA Generic Drug Database – Abbreviated New Drug Applications.
5. FDA Approved Oncology Drugs – ALK inhibitors.
6. Novartis Patent Portfolio – Supplemental delivery method patents.
7. Novartis Annual Report – Intellectual Property.
8. FDA Patent Examination Guidelines – Delivery system patents.
9. CMS Medicare Part D Drug Pricing Report.
10. FDA Regulatory Affairs Bulletin – Oncology drug exclusivity updates.